Introduction: In chronic myeloid leukemia patients, second-line treatment requires careful consideration of response and tolerability. As most patients need a more efficient tyrosine kinase inhibitor, ponatinib at a lowered dose should be evaluated in this setting. Methods: We studied a lowered dose of 30 mg ponatinib in second line in patients selected toward a low cardiovascular risk. In 22 screened patients, ponatinib was started in 18 patients previously treated with imatinib (n = 3), dasatinib (n = 9), or nilotinib (n = 6). Patients were frequently monitored for cardiovascular toxicities by testing of blood pressure, vital signs, ankle brachial index or duplex, oral glucose tolerance test, echocardiography, ECG, and fundoscopy. The study protocol allowed dose reductions in patients achieving MMR. Both previously resistant or intolerant patients were recruited. Results: No serious cardiovascular events were observed, and low-grade cardiovascular toxicity was negligible. By 12 months, 13 patients (92.9%) were in complete hematologic remission, 10 patients (55.6%) were in MMR, and 5 patients (27.8%) were in MR4. Most importantly, we demonstrated that thorough monitoring of cardiovascular risk is feasible. Conclusions: We demonstrated that a lowered dose of 30 mg ponatinib in selected patients can be maintained without serious cardiovascular complications, provided cardiovascular risk monitoring is performed. In our patient cohort, this approach resulted in favorable response rates.

1.
Hochhaus
A
,
Larson
RA
,
Guilhot
F
,
Radich
JP
,
Branford
S
,
Hughes
TP
, et al
.
Long-term outcomes of imatinib treatment for chronic myeloid leukemia
.
N Engl J Med
.
2017
;
376
(
10
):
917
27
.
2.
Kantarjian
HM
,
Hughes
TP
,
Larson
RA
,
Kim
DW
,
Issaragrisil
S
,
le Coutre
P
, et al
.
Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis
.
Leukemia
.
2021
;
35
(
2
):
440
53
.
3.
Cortes
JE
,
Saglio
G
,
Kantarjian etbal
HM
.
Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial
.
J Clin Oncol
.
2016
;
34
(
20
):
2333
40
.
4.
Mahon
FX
,
Pfirrmann
M
,
Dulucq
S
,
Hochhaus
A
,
Panayiotidis
P
,
Almeida
A
, et al
.
European stop tyrosine kinase inhibitor trial (EURO-SKI) in chronic myeloid leukemia: final analysis and novel prognostic factors for treatment-free remission
.
J Clin Oncol
.
2024
;
42
(
16
):
1875
80
.
5.
Hochhaus
A
,
Baccarani
M
,
Silver
RT
,
Schiffer
C
,
Apperley
JF
,
Cervantes
F
, et al
.
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
.
Leukemia
.
2020
;
34
(
4
):
966
84
.
6.
Cortes
JE
,
Kim
D-W
,
Pinilla-Ibarz
J
,
le Coutre
PD
,
Paquette
R
,
Chuah
C
, et al
.
Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial
.
Blood
.
2018
;
132
(
4
):
393
404
.
7.
Lipton
JH
,
Chuah
C
,
Guerci-Bresler
A
,
Rosti
G
,
Simpson
D
,
Assouline
S
, et al
.
Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial
.
Lancet Oncol
.
2016
;
17
(
5
):
612
21
.
8.
Cortes
J
,
Apperley
J
,
Lomaia
E
,
Moiraghi
B
,
Undurraga Sutton
M
,
Pavlovsky
C
, et al
.
Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial
.
Blood
.
2021
;
138
(
21
):
2042
50
.
9.
Castagnetti
F
,
Pane
F
,
Rosti
G
,
Saglio
G
,
Breccia
M
.
Dosing strategies for improving the risk-benefit profile of ponatinib in patients with chronic myeloid leukemia in chronic phase
.
Front Oncol
.
2021
;
11
:
1
7
.
10.
Saussele
S
,
La Rosée
P
,
Kiani
A
,
Haverkamp
W
,
Jentsch-Ullrich
K
,
Stegelmann
F
, et al
.
Addendum to the German consensus recommendations on ponatinib in the treatment of chronic myeloid leukemia
.
Acta Haematol
.
2024
;
147
(
3
):
344
51
.
11.
Iurlo
A
,
Cattaneo
D
,
Bucelli
C
,
Spallarossa
P
,
Passamonti
F
.
Cardiovascular adverse events of tyrosine kinase inhibitors in chronic myeloid leukemia: clinical relevance, impact on outcome, preventive measures and treatment strategies
.
Curr Treat Options Oncol
.
2023
;
24
(
12
):
1720
38
.
12.
Nicolini
FE
,
Charbonnier
A
,
Escoffre-Barbe
M
,
Jourdan
E
,
Roth-Guepin
G
,
Berger
MG
, et al
.
18-Months follow-up of the Trial of Imatinib after Ponatinib Induction (TIPI) in the front-line treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) setting
.
Blood
.
2024
;
144
(
Suppl 1
):
478
.
You do not currently have access to this content.